5-硝基-2-(正丙氨基)-吡啶 | 25948-11-2

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 5-硝基-2-(正丙氨基)-吡啶
• 中文别名: 5-硝基-2-丙氨基)吡啶
• 英文名称: 2-n-Propylamino-5-nitro-pyridin
• 英文别名: (5-nitro-pyridin-2-yl)-propyl-amine；5-nitro-2-n-propylaminopyridine；5-Nitro-2-(N-propylamino)pyridine；5-nitro-N-propylpyridin-2-amine
• CAS: 25948-11-2
• 化学式: C₈H₁₁N₃O₂
• mdl: MFCD00084819
• 分子量: 181.194
• InChiKey: KZWODZHPEMBNTR-UHFFFAOYSA-N

物化性质

• 熔点：
  94-96 °C
• 沸点：
  314.3°C (rough estimate)
• 密度：
  1.2444 (rough estimate)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解。避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

SDS

Name:	5-Nitro-2-N-(Propylamino)Pyridine Material Safety Data Sheet
Synonym:	N-(5-Nitropyridyl)Propylamin
CAS:	25948-11-2

Section 1 - Chemical Product MSDS Name:5-Nitro-2-N-(Propylamino)Pyridine Material Safety Data Sheet
Synonym:N-(5-Nitropyridyl)Propylamin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
25948-11-2	5-Nitro-2-(N-Propylamino)-Pyridine	ca 100	247-357-0

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
Causes gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 25948-11-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: not available
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 94.00 - 96.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H11N3O2
Molecular Weight: 181.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 25948-11-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Nitro-2-(N-Propylamino)-Pyridine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 25948-11-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 25948-11-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 25948-11-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

文献信息

• [EN] SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2)<br/>[FR] COMPOSÉS N-HÉTÉROCYCLIQUES AROMATIQUES SUBSTITUÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE ACTIVÉE PAR MITOGÈNE INTERAGISSANT AVEC LA KINASE 1 (MNK1) ET LA KINASE 2 (MNK2)
  申请人：UNIV NORTHWESTERN

  公开号：WO2017075367A1

  公开（公告）日：2017-05-04

  Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.

  揭示了替代芳香族N-杂环化合物。所述化合物通常表现出激酶抑制活性，例如，抑制Mnk1激酶和/或Mnk2激酶。所述化合物可用于制备药物组合物和治疗与Mnk1激酶活性和/或Mnk2激酶活性相关的疾病或紊乱的方法，如癌症、糖尿病、自闭症和脆性X综合征。
• SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
  申请人：Bignan Gilles

  公开号：US20110294780A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性腰部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，遗传性骨发育不全，骨溶解性骨转移，软骨软化症，骨质疏松症，帕金森病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的方法。
• [EN] IMIDAZO '1,2-A' PYRAZINE COMPOUNDS WHICH INTERACT WITH PROTEIN KINASES<br/>[FR] COMPOSES DE 1,2-A' PYRAZINE IMIDAZO INTERAGISSANT AVEC LES PROTEINES KINASES
  申请人：BIOFOCUS DISCOVERY LTD

  公开号：WO2005085252A1

  公开（公告）日：2005-09-15

  The present invention relates to a novel compounds of formula I, to pharmaceutical compounds, to processes for their preparation, as well as to the use of the compounds in the inhibition of protein kinases, in particular serine/threonine kinases, more particularly mitogen activated protein kinase, more particularly the c-Jun NH2-teminal kinases (JNKs). The invention also relates to the compounds for use in medicine and particularly n the prevention and/or treatment of a wide variety of diseases including inflammatory disorders, cancer, angiogenesis, diabetes, metabolic disease and neurological disorders.

  本发明涉及一种式I的新型化合物，以及制备这些化合物的药物化合物的方法，以及化合物在抑制蛋白激酶中的应用，特别是丝氨酸/苏氨酸激酶，更具体地是丝氨酸/苏氨酸激酶，更具体地是c-Jun NH2-teminal激酶（JNKs）。该发明还涉及这些化合物在医学上的应用，特别是在预防和/或治疗包括炎症性疾病、癌症、血管生成、糖尿病、代谢性疾病和神经系统疾病在内的各种疾病中的应用。
• Mittel zum Färben von Haaren
  申请人：RÜTGERSWERKE AKTIENGESELLSCHAFT

  公开号：EP0137524A1

  公开（公告）日：1985-04-17

  Die Erfindung beschreibt neue Kuppler- oder Nuanceurkomponenten, die in Kombination mit einschlägigen Entwicklern zum Färben von Haaren verwendet werden. Diese Kupplerkomponenten sind Nitropyridinderivate der allgemeinen Formel wobei die Substituenten X, Y, R, und R2 die in den Ansprüchen gegebenen Bedeutungen haben.

  本发明描述了与相关显影剂结合使用的新型耦合剂或微染剂成分，用于染发。这些耦合剂成分是通式如下的硝基吡啶衍生物 其中取代基 X、Y、R 和 R2 的含义见权利要求书。
• THERAPEUTIC QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1218355A1

  公开（公告）日：2002-07-03

表征谱图